Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Jeffrey Jones; Chief Financial Officer, Senior Vice President - Finance; Cohu Inc. Luis Muller; President, Chief Executive Officer, Director; Cohu Inc. Craig Ellis; ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Retail’s AI reinvention is underway. The winners will be those who invest responsibly in the technology, while also ...

Ended 2024 with $777 Million in Cash & Short-Term Investments ~ ~ Exploring Mergers & Acquisitions across Multiple Industries, Evolving TMTG into a Holding Company ~ ~ Approaching End of Beta Testing ...

DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporates visual stimulation in an interactive manner to enable ...

Lower interest rates over the next several years will stifle net interest income growth. The company may have a greater opportunity to recruit advisors as it fills holes in its geographic footprint ...

DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporates visual stimulation ...

Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...

When organizations prioritize a clear purpose over profit, they have a positive influence on consumers and stakeholders of ...